INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide \[[@R1]\]. More than 500,000 patients are newly diagnosed with HCC every year, and 50% of all cases and deaths are in China \[[@R2], [@R3]\]. Among these, most are hepatitis B virus (HBV)-related HCC patients. Although advances in treatment, especially in surgical techniques and molecular targeted therapy, have improved the survival rates of HCC patients, the long term prognosis after surgical resection remains very poor \[[@R4]--[@R6]\]. Thus, early diagnosis and treatment are very important to improve the prognosis of HCC patients \[[@R7]--[@R10]\]. Multiple clinical factors have been used as indicators for the diagnosis and evaluation of HCC, for instance, drinking status, chronic HBV or hepatitis C virus (HCV) infections, large tumor size, vascular invasion, positive portal vein thrombosis, serum alpha fetoprotein (AFP) and Barcelona Clinic Liver Cancer (BCLC) stage \[[@R11]--[@R13]\]. Current indicators used to predict HCC outcomes and the prognosis of HCC patients are not sufficient. Thus, it is urgent to identify potential biomarkers for improving the efficacy of prognosis prediction and the clinical outcomes of HCC patients.

The integrin family consists of 18 α and 8 β subunits that form 24 known αβ-heterodimers. Both α and β subunits have a large NH~2~-terminal extracellular domain, a single transmembrane domain and a short non-catalytic cytoplasmic tail \[[@R14], [@R15]\]. Integrins are involved in a wide range of biological activities and pathological processes, especially carcinogenesis and cancer progression \[[@R16], [@R17]\]. They regulate cell--cell and cell--ECM interactions, and this 'outside-in' signaling activates a number of signaling pathways that are important in the regulation of cell shape, survival, gene transcription and migration \[[@R18], [@R19]\]. They also interact with growth factors or chemokines to regulate cell growth and differentiation \[[@R14], [@R20]\]. Thus, targeting integrins and their associated signaling pathways, which are involved in tumor proliferation, migration, invasion and metastasis, may be a novel strategy for the diagnosis and treatment of cancers as well as certain non-neoplastic conditions \[[@R21]\]. Studies have also reported that effective blockage of integrins and ECM interactions impairs several important aspects of tumor biology and increases sensitivity to existing chemotherapy \[[@R22], [@R23]\]. Anti-integrin antagonists used in combination with current chemotherapeutic drugs have been shown to have roles in preventing drug resistance and tumor relapse \[[@R24]\].

In this study, we evaluated the prognostic predictive value of integrin family genes and *ITGA1* single nucleotide polymorphism (SNP) rs988574 in HBV-related HCC patients by performing prognostic analysis in 221 newly diagnosed pathologically confirmed HBV-related HCC patients. First, we found that *ITGA5* and *ITGB5* are more highly expressed in HBV-related HCC tissues than adjacent normal tissues. Conversely, *ITGA2B* is more highly expressed in adjacent normal tissues than in HBV-related HCC tissues. We also found that higher expression of *ITGA5*, *ITGB5* and *ITGA2B* predicted worse prognosis in HBV-related HCC patients, and patients with lower expression of both *ITGA5* and *ITGB5* had the best prognosis. In addition, we found that patients carrying the AG or GG genotypes at rs988574 had better prognosis than those with the AA genotype.

RESULTS {#s2}
=======

Patient characteristics and clinical predictors {#s2_1}
-----------------------------------------------

The clinical and pathologic characteristics of the patients are shown in Table [1](#T1){ref-type="table"}. Overall, 55 female patients and 430 male patients were included. Among them, 307 were Han Chinese and 178 were minorities. The median survival times were 57 and 51 months for patients aged ≤46 years and \>46 years, respectively. As shown in Table [1](#T1){ref-type="table"} univariate analysis indicated that patients with BCLC stages B and C (HR = 1.92, 95%CI = 1.35--2.73; HR = 3.1, 95%CI = 2.31--4.16, respectively), Child-Pugh class B (HR = 1.68, 95%CI = 1.21--2.33), non-radical resection (HR = 0.76, 95%CI = 0.59--0.99), non-antiviral therapies (HR = 0.72, 95%CI = 0.53--0.98), AFP ≥ 300ng/ml (HR = 1.30, 95%CI = 0.99--1.71), tumor size ≥ 5 cm (HR = 2.04, 95%CI = 1.49--2.80), multiple tumors (n \> 1) (HR = 1.61, 95%CI = 1.23--2.12) and presence of PVTT (HR = 2.40, 95%CI = 1.12--5.12) had higher risk of death when compared with patients with BCLC stage A, child-Pugh class A, radical resection, antiviral therapies, AFP \< 300 ng/ml, tumor size \< 3cm, single tumor (n = 1) and absence of PVTT, respectively. In addition, clinical features including age, gender, race, BMI, drinking status, smoking status, adjuvant TACE and cirrhosis were found to have no effect on the OS of HBV-related HCC patients in our study.

###### Univariate Cox proportional hazards analysis of clinicopathological characteristics and overall survival in HBV-related HCC patients

  Variables                 Patients (n=485)   OS                         
  ------------------------- ------------------ ----- -------------------- --------------
  Age (yr)                                                                
   ≤ 46                     260                57    Ref.                 
   \> 46                    225                51    0.97 (0.74--1.25)    0.789
  Gender                                                                  
   male                     430                51    Ref.                 
   female                   55                 80    0.75 (0.47--1.18)    0.208
  Race                                                                    
   Han                      307                68    Ref.                 
   Minority                 178                51    1.10 (0.84--1.45)    0.473
  BMI                                                                     
   ≤ 25                     401                58    Ref.                 
   \> 25                    84                 57    0.95 (0.68--1.32)    0.737
  Smoking status                                                          
   None                     318                71    Ref.                 
   Ever                     167                42    1.20 (0.91--1.57)    0.191
  Drinking status                                                         
   None                     295                71    Ref.                 
   Ever                     190                48    1.18 (0.91--1.53)    0.219
  Adjuvant TACE ^a^                                                       
   No                       212                88    Ref.                 
   Yes                      273                47    1.14 (0.87--1.49)    0.340
  BCLC stage                                                              
   A                        284                95    Ref.                 **\< 0.001**
   B                        80                 47    1.92 (1.35--2.73)    **\< 0.001**
   C                        121                24    3.10 (2.31--4.16)    **\< 0.001**
  Child--Pugh class                                                       
   A                        403                65    Ref.                 
   B                        82                 34    1.68 (1.21--2.33)    **0.002**
  Cirrhosis                                                               
   No                       58                 82    Ref.                 
   Yes                      426                51    1.21 (0.80--1.84)    0.361
  Antiviral therapy^b^                                                    
   No                       315                47    Ref.                 
   Yes                      170                81    0.72 (0.53--0.98)    **0.036**
                                                                          
  AFP                                                                     
   ≤ 400 (ng/ml)            247                63    Ref.                 
   \> 400 (ng/ml)           202                42    1.30 (0.99--1.71)    0.059
   missing                  36                                            
  Radical resection                                                       
   No                       205                41    Ref.                 
   Yes                      268                74    0.76 (0.59--0.99)    **0.044**
   missing                  12                                            
  Pathological grade                                                      
   Well                     27                 79    Ref.                 0.761
   Moderately               372                51    1.25 (0.68--2.30)    0.470
   Poorly                   13                 NA    1.15 (0.40--3.31)    0.797
   missing                  73                                            
  Oncological behavior                                                    
  Tumor size                                                              
   ≤ 5 cm                   155                123   Ref.                 
   \> 5 cm                  330                40    2.04 (1.49--2.80)    **\< 0.001**
  No. of tumors                                                           
   Single (n = 1)           356                63    Ref.                 
   Multiple (n \> 1)        129                35    1.61 (1.23--2.12)    **0.001**
  Regional invasion                                                       
   Absence                  412                68    Ref.                 
   Presence                 73                 37    1.62 (1.137--2.30)   **0.007**
  Intrahepatic metastasis                                                 
   Absence                  264                81    Ref.                 
   Presence                 221                35    1.80 (1.38--2.33)    **\< 0.001**
  Vascular invasion                                                       
   Absence                  399                78    Ref.                 
   Presence                 86                 18    3.16 (2.35--4.25)    **\< 0.001**
  PVTT                                                                    
   No                       409                76    Ref.                 **\< 0.001**
   vp1                      11                 28    2.40 (1.12--5.12)    **0.024**
   vp2                      17                 17    3.44 (1.99--5.96)    **\< 0.001**
   vp3                      40                 17    2.89 (1.96--4.27)    **\< 0.001**
   vp4                      8                  8     5.84 (2.72--12.54)   **\< 0.001**

Note: \*HR and *P*-value for univariate survival analysis;^a^Adjuvant TACE post hepatectomy;^b^Adjuvant antiviral therapy post hepatectomy;

OS, overall survival; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., reference; PVTT, portal vein tumor thrombus.

*ITGA1* SNP rs988574-AA predicted worse OS in HBV-related HCC patients {#s2_2}
----------------------------------------------------------------------

The SNP functional prediction results showed that rs988574 located in a splice site and the non-synonymous mutation was possibly damaging for gene expression as predicted by Polyphen in SNP selection tools. In this study, we found that patients carrying the AG/GG alleles of rs988574 had a significantly better prognosis when compared to patients with the AA genotype. Cox proportional hazards regression analysis showed that rs988574 was significantly associated with prognosis when adjusting for age, gender, race, smoking status, drinking status, BMI, child-Pugh class, cirrhosis, BCLC stage, pathological grade, TACE status post hepatectomy, antiviral therapy after hepatectomy, radical resection and serum AFP levels (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Figure [1A](#F1){ref-type="fig"} shows that patients with the AG genotype had a significantly favorable OS, compared to patients with the AA genotype. Additionally, when combining carriers of the AG and GG alleles, patients with the AA genotype had a worse prognosis (Figure [1B](#F1){ref-type="fig"}). The adjusted survival curve shows a significant difference in OS between patients with the AG and GG genotypes of rs988574 compared to those with the AA genotype (*P* = 0.025, HR = 0.69 95%CI = 0.50--0.96; Table [3](#T3){ref-type="table"}).

###### Multivariate Cox proportional hazards ratio analysis of *ITGA1* SNPs and overall survival or relapse free survival in HBV-related HCC patients

  SNP            Chr     Position       Gene        Allele    Function            MAF        os          
  -------------- ------- -------------- ----------- --------- ------------------- ---------- ----------- ------------
  rs1531545      5       52193287       ITGA1       C/T       Synonymous          0.34       0.208       0.301
  rs4145748      5       52201722       ITGA1       C/T       Nonsynonymous       0.09       0.414       0.455
  rs2279587      5       52214581       ITGA1       G/A       Nonsynonymous       0.11       0.257       0.312
  rs12520591     5       52229745       ITGA1       T/G       Nonsynonymous       0.11       0.378       0.356
  **rs988574**   **5**   **52240810**   **ITGA1**   **A/G**   **Nonsynonymous**   **0.14**   **0.002**   **0.043£**
  rs2230392      17      48155425       ITGA3       G/A       Nonsynonymous       0.29       0.219       0.374
  rs1143674      2       182374534      ITGA4       A/G       Synonymous          0.36       0.453       0.499
  rs1143676      2       182395345      ITGA4       G/A       Nonsynonymous       0.12       0.182       0.386
  rs7562325      2       182399097      ITGA4       T/C       Synonymous          0.36       0.420       0.429
  rs11895564     2       173339808      ITGA6       G/A       Nonsynonymous       0.06       0.516       0.604
  rs1800974      12      56089357       ITGA7       C/T       Nonsynonymous       0.06       0.108       0.156
  rs2298033      10      15649710       ITGA8       G/A       Nonsynonymous       0.06       0.886       0.901
  rs2507941      3       37536056       ITGA9       C/T       Synonymous          0.08       0.737       0.825
  rs267561       3       37574951       ITGA9       G/A       Nonsynonymous       0.22       0.284       0.355
  rs2274616      1       145536082      ITGA10      G/A       Nonsynonymous       0.07       0.479       0.622
  rs2230433      16      30518041       ITGAL       G/C       Nonsynonymous       0.19       0.766       0.812
  rs871443       17      73753503       ITGB4       T/C       Nonsynonymous       0.37       0.580       0.635
  rs2291089      3       124515636      ITGB5       C/T       Nonsynonymous       0.10       0.299       0.427

Note: Cox P adjusted for age, gender, BMI, race, smoking status, drinking status, Child-Pugh class, cirrhosis, BCLC stage, pathological grade, TACE status post hepatectomy, antiviral therapy after hepatectomy, radical resection, serum AFP levels, intrahepatic metastasis, vascular invasion and PVTT. £Sequencing map of rs988574 was shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; OS, overall survival.

###### Multivariate Cox proportional hazards ratio analysis of *ITGA1* SNP rs988574 and overall survival in HBV-related HCC patients

  SNP        Patients (n=485)   OS                                                       
  ---------- ------------------ ---- ------------------- ----------- ------------------- -----------
  rs988574                                                                               
  AA         345                42   Ref.                **0.003**   Ref.                0.052
  AG         135                88   0.65 (0.47--0.88)   **0.006**   0.67 (0.48--0.93)   **0.018**
  GG         5                  14   2.53 (0.94--6.83)   0.067       1.30 (0.40--4.25)   0.659
  AG+GG      140                82   0.68 (0.51--0.93)   **0.014**   0.69 (0.50--0.96)   **0.025**

Note: \*Adjusted for age, gender, BMI, race, smoking status, drinking status, Child-Pugh class, cirrhosis, BCLC stage, pathological grade, TACE status post hepatectomy, antiviral therapy after hepatectomy, radical resection, serum AFP levels, intrahepatic metastasis, vascular invasion and PVTT.

SNP, single nucleotide polymorphism; OS, overall survival; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., reference.

![Prognostic value of *ITGA1* SNP rs988574 genotype in HBV-related HCC patients\
**(A, B)** Kaplan-Meier graphs representing the probabilities of overall survival in HCC patients; **(C)** Kaplan-Meier graph showing the overall survival by rs988574 genotype combined with serum AFP level in HBV-related HCC patients.](oncotarget-08-76816-g001){#F1}

Stratified analysis also utilized to investigate the association between clinicopathological features and HBV-related HCC outcomes. In stratified analyses, the AG/GG genotype ofrs988574 significantly decreased risk of death among HBV-related HCC patients with BCLC A stage, intrahepatic metastasis, advanced pathological grade, adjuvant TACE and patients without PVTT and vascular invasion (Figure [2](#F2){ref-type="fig"}) after hepatectomy, compared to patients with the AA genotype.

![Stratified analysis of association between *ITGA1*-rs988574 polymorphisms and OS in HBV-related HCC patients\
Variables were stratified according to favorable and adverse strata.](oncotarget-08-76816-g002){#F2}

Prognostic value of rs988574 combined with serum AFP level on OS in HBV-related HCC patients {#s2_3}
--------------------------------------------------------------------------------------------

In this study, we further analyzed the combined effect of rs988574 and serum AFP level on the prognosis of patients. According to rs988574 genotype and serum AFP level, patients were classified into four groups: AFP ≤ 400 ng/mL with AG/GG genotype, AFP ≤ 400 ng/mL with AA genotype, AFP \> 400 ng/mL with AG/GG genotype and AFP \> 400 ng/mL with AA genotype (Table [4](#T4){ref-type="table"}). Multivariate Cox regression analysis indicated that, as compared to patients with AG/GG genotype and low serum AFP (AFP ≤ 400 ng/ml), patients with the AA genotype and a high serum AFP (AFP \> 400 ng/mL) had a significantly higher risk for death (adjusted *P* = 0.026, adjusted HR = 1.75, 95%CI = 1.07--2.85; Table [4](#T4){ref-type="table"} and Figure [1C](#F1){ref-type="fig"}).

###### Multivariate Cox proportional hazards ratio analysis combining *ITGA1* SNP rs988574 and APF level for overall survival in HBV-related HCC patients

  SNP                          MST (months)   HR (95%CI)          P           HR \*(95%CI)        P \*
  ---------------------------- -------------- ------------------- ----------- ------------------- -----------
  rs988574                                                                                        
  AFP ≤ 400 (ng/mL) +AG/GG     79             Ref.                **0.019**   Ref.                0.094
  AFP \> 400 (ng/mL) + AG/GG   88             1.41 (0.80--2.48)   0.230       1.23 (0.68--2.22)   0.490
  AFP ≤ 400 (ng/mL) + AA       57             1.59 (1.00--2.53)   **0.048**   1.60 (0.99--2.59)   0.056
  AFP \> 400 (ng/mL) + AA      36             2.05 (1.28--3.27)   **0.003**   1.75 (1.07--2.85)   **0.026**

Note:\*Adjusted for age, gender, BMI, race, smoking status, drinking status, Child-Pugh class, cirrhosis, BCLC stage, pathological grade, TACE status post hepatectomy, antiviral therapy after hepatectomy, radical resection, intrahepatic metastasis, vascular invasion and PVTT.

SNP, single nucleotide polymorphism; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., reference.

The mRNA expression level of integrins in HCC tissues and adjacent normal tissues {#s2_4}
---------------------------------------------------------------------------------

The integrin family consists of 24 genes, widely studied in the progression of various cancers. To clarify the expression pattern of integrin family members in HBV-related HCC patients, we compared the mRNA expression levels between HBV-related HCC tissues and adjacent normal tissues. The results showed that nine of the integrin gene family members have a higher expression in HBV-related HCC tissues compared to adjacent normal tissues (Figure [3A](#F3){ref-type="fig"}; *P* \< 0.001). In a multivariate Cox proportional hazards ratio analysis adjusting for age, gender, cirrhosis, BCLC stage and serum AFP levels, we found that among the 24 integrin family genes, *ITGA5*, *ITGB5* and *ITGA2B* were significantly associated with prognosis in terms of OS or RFS of patients with HBV-related HCC (Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}; *P* \< 0.05). Then, we compared the expression of *ITGA5*, *ITGB5* and *ITGA2B* in 221 HBV-related HCC tissues and 221 adjacent normal tissues, and the results showed that *ITGA5* and *ITGB5* are more highly expressed in HBV-related HCC tissues than adjacent normal tissues, while *ITGA2B* had a lower expression level in HBV-related HCC tissues than adjacent normal tissues (Figure [3B](#F3){ref-type="fig"}; *P* \< 0.001).

![Integrin family genes' expression levels in HCC tissues and adjacent normal tissues\
**(A)** Histogram of log-fold change showing the 24 integrin family members' expression levels in HBV-related HCC tissues compared with adjacent normal tissues. **(B)** Comparison of the expression of *ITGA5*, *ITGB5* and *ITGA2B* in 221 HBV-related HCC tissues and adjacent normal tissues. *P-*value indicates statistical significance analyzed by Student\'s t-test.](oncotarget-08-76816-g003){#F3}

###### Multivariate Cox proportional hazards ratio analysis of integrin genes expression and overall survival or relapse free survival in HBV-related HCC patients

  Integrins        OS            RFS                            
  ---------------- ------------- ---------------- ------------- -----------
  **Log-rank P**   **Cox P\***   **Log-rank P**   **Cox P\***   
  ITGA1            0.861         0.438            0.793         0.471
  ITGA2            0.241         0.762            0.305         0.727
  **ITGA2B**       0.230         **0.064**        0.172         **0.032**
  ITGA3            0.209         0.217            0.721         0.997
  ITGA4            0.138         0.327            0.069         0.095
  **ITGA5**        **0.013**     **0.041**        **0.003**     **0.006**
  ITGA6            0.885         0.337            0.377         0.089
  ITGA7            0.126         0.169            0.438         0.407
  ITGA8            0.579         0.826            0.877         0.784
  ITGA9            0.481         0.813            0.094         0.072
  ITGA10           0.509         0.567            0.308         0.510
  ITGAE            0.528         0.464            0.906         0.913
  ITGAL            0.803         0.913            0.562         0.672
  ITGAM            0.463         0.677            0.439         0.777
  ITGAV            0.411         0.172            0.825         0.692
  ITGAX            0.877         0.079            0.517         0.879
  ITGB1            0.403         0.822            0.340         0.846
  ITGB2            0.902         0.654            0.514         0.298
  ITGB3            0.614         0.154            0.042         0.064
  ITGB4            0.716         0.983            0.735         0.407
  ITGB5            **0.016**     **0.048**        0.069         **0.042**
  ITGB6            0.434         0.928            0.625         0.768
  ITGB7            0.451         0.635            0.523         0.591
  ITGB8            0.945         0.919            0.615         0.760

Note: The 75th percentile of mRNA expression in the total population was used as the cutoff point to define lower and higher expression groups. \*Cox P adjusted for age, gender, cirrhosis, BCLC stage and serum AFP levels.

OS, overall survival; RFS, relapse-free survival.

###### Multivariate Cox proportional hazards ratio analysis of *ITGA5*, *ITGB5* and *ITGA2B* expression and overall survival or relapse-free survival in HBV-related HCC patients

  Gene               Patients (n=221)   OS              RFS                                                                        
  ------------------ ------------------ --------------- ------------------- ------------------ --------------- ------------------- -----------
  **MST (months)**   **HR\* (95%CI)**   **P value\***   **MRT (months)**    **HR\* (95%CI)**   **P value\***                       
  ITGA5                                                                                                                            
   Lower             165                67.4            Ref.                **0.041**          51.6            Ref.                **0.006**
   Higher            56                 45.9            1.64 (1.02--2.63)                      21.3            1.75 (1.18--2.62)   
  ITGB5                                                                                                                            
   Lower             165                67.4            Ref.                **0.048**          49.1            Ref.                **0.042**
   Higher            56                 53              1.62 (1.00--2.60)                      23.6            1.53 (1.02--2.31)   
  ITGA2B                                                                                                                           
   Lower             165                67.3            Ref.                0.064              48              Ref.                **0.032**
   Higher            56                 58.4            1.58 (0.97--2.73)                      24.6            1.56 (1.04--2.33)   

Note: The 75th percentile of mRNA expression in the total population was used as the cutoff point to define lower and higher expression groups. \*Adjusted for age, gender, cirrhosis, BCLC stage and serum AFP levels.

OS, overall survival; RFS, relapse-free survival; MST, median survival time; MRT, median relapse time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., reference.

The adjusted survival curves showed a significant difference in OS and RFS between patients with higher versus lower *ITGA5*, *ITGB5* and *ITGA2B* expression levels. (Figure [4](#F4){ref-type="fig"}). The mRNA expression levels of *ITGA5*, *ITGB5* and *ITGA2B* were independent prognostic indicators in HBV-related HCC patients (Table [6](#T6){ref-type="table"}). Co-expression analysis indicated that *ITGA5* mRNA expression had a significantly positive correlation with *ITGB5* (r=0.32, *P\<*0.001) in tumor tissue, whereas *ITGA2B* had a significantly negative correlation with *ITGA5* (r=-0.142, *P* =0.035) and *ITGB5* (r=-0.34, *P* \<0.001), respectively.

![Prognostic value of *ITGA5*, *ITGB5* and *ITGA2B* expression levels in HBV-related HCC patients\
Kaplan-Meier plot representing the probabilities of overall survival and relapse-free survival in HCC patients stratified according to the expression levels of *ITGA5* **(A, B)**, *ITGB5* **(C, D)** and *ITGA2B* **(E, F)**.](oncotarget-08-76816-g004){#F4}

Prognostic prediction of *ITGA5* expression combined with *ITGB5* expression in HBV-related HCC patients {#s2_5}
--------------------------------------------------------------------------------------------------------

Base on the results of the co-expression and survival analysis for individual integrin genes, we analyzed the prognostic predictive value of combining *ITGA5* and *ITGB5* expression. The results showed that patients with higher expression of both *ITGA5* and *ITGB5* had the worst OS and RFS compared to patients with lower expression of these genes (Figure [5](#F5){ref-type="fig"} and Table [7](#T7){ref-type="table"}; *P =* 0.017 and 0.002, respectively).

![Prognostic value of *ITGA5* expression combined with *ITGB5* expression in HBV-related HCC patients\
Kaplan-Meier plots showing the overall survival **(A)** and relapse-free survival **(B)** of combining *ITGA5* and *ITGB5* mRNA expression.](oncotarget-08-76816-g005){#F5}

###### Multivariate Cox proportional hazards ratio analysis combining *ITGA5* and *ITGB5* expression and overall survival or relapse-free survival in HBV-related HCC patients

  Groups (ITTGA5 & ITGB5)   Patients (n=221)   OS              RFS                                                                        
  ------------------------- ------------------ --------------- ------------------- ------------------ --------------- ------------------- -------------
  **MST (months)**          **HR\* (95%CI)**   **P value\***   **MRT (months)**    **HR\* (95%CI)**   **P value\***                       
  Both Lower                130                67.4            Ref.                **0.017**          54.8            Ref.                **0.002**
  Lower/Higher              70                 53.3            1.37 (0.84--2.25)   0.212              36.0            1.38 (0.91--2.07)   0.127
  Both Higher               21                 17.6            2.58 (1.34--4.95)   **0.004**          13.1            2.89 (1.61--5.18)   **\<0.001**

Note: The 75th percentile of mRNA expression in the total population was used as the cutoff point to define lower and higher expression groups. \*Adjusted for age, gender, cirrhosis, BCLC stage and serum AFP levels.

OS, overall survival; RFS, relapse-free survival; MST, median survival time; MRT, median relapse time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., reference.

DISCUSSION {#s3}
==========

In this study, we examined whether genetic polymorphisms in the integrin gene family are associated with the OS of HBV-related HCC patients and explored the expression pattern and prognostic predictive value of these genes using GEO data. We found that the AG/GG genotypes of rs988574 (*ITGA1*) are significantly associated with better OS compared with the AA genotype in HBV-related HCC patients. In addition, we found that patients with the AA genotype combined with high serum AFP (AFP \> 400 ng/mL) predicted the highest risk of death. Additionally, among the 24 integrin family members, nine had higher expression in HBV-related HCC tissues compared to adjacent normal tissues, while the other integrin genes showed the opposite expression pattern. Specifically, the expression of *ITGA5* and *ITGB5* were higher in HCC tissues than in adjacent tissues. In contrast, the expression of *ITGA2B* was the opposite, and significantly negative correlation with *ITGA5* and *ITGB5* in tumor tissue. Furthermore, we found that the expression level of *ITGA5*, *ITGB5* and *ITGA2B* were associated with the prognosis of HBV-related HCC patients; lower expression of these genes predicted a better OS and RFS compared with higher expression. Furthermore, we found that patients with the combination of lower expression of both *ITGA5* and *ITGB5* had the best OS and RFS.

Our SNP functional prediction results show that rs988574 disrupts a splice site, and this non-synonymous mutation was possibly damaging for gene expression as predicted by Polyphen in SNP selection tools. This may a potential mechanism that AA polymorphism of rs988574 affects functionality of *ITGA1* in respect to the HBV-related HCC. Moreover, we demonstrated that the SNP rs988574 in *ITGA1* may serve as an independent prognostic marker in HBV-related HCC patients. Once validated, these genes, either alone or in combination with each other or other traditional clinical-prognostic factors, may be used as new targets for the treatment of HBV-related HCC patients.

Integrins are a large family of cell surface receptors that bind ECM proteins to regulate attachment, cell proliferation, differentiation, motility and other essential cell functions \[[@R25]\]. They are critically important for both health and disease by participating in diverse human pathologies including thrombotic diseases, infectious diseases, inflammation, fibrosis and cancer \[[@R24]\]. Integrins play an important role in cancer survival, proliferation, growth and metastasis \[[@R26]--[@R28]\]. Apart from their correlation with cancer prognosis, integrins can also protect cells from stress, leading to cancer cell resistance to radio- and chemotherapy \[[@R29]\]. Additionally, integrin inhibition has been shown to enhance the cytotoxic efficacy of radiation and chemotherapeutics \[[@R30]\]. Reports have also shown that integrins are sensitive to pharmacological blockade, making them exciting pharmacological targets for anticancer therapies \[[@R31]\]. Indeed, several integrin inhibitors have been designed and have undergone clinical trials, and all were shown to be nontoxic.

Some studies have shown that integrins, such as beta1, beta3 and beta5, play an important role in cell growth, proliferation, invasion and migration \[[@R31]\]. It has also been demonstrated that integrin levels are frequently elevated in aggressive tumors, implying that these proteins might be promising targets for cancer treatments \[[@R32]\]. ITGA5 is a member of the integrin family that mediates cell-to-cell adhesion, migration and anoikis in virous tumors both *in vivo* and *in vitro* \[[@R33], [@R34]\]. Additionally, ITGA5 promotes tumor cell adhesion and migration through activating focal adhesion kinase (FAK), and an antibody (Volociximab) or a non--RGD-based peptide inhibitor (ATN-161), which blocks the function of the heterodimer function, significantly inhibits the growth and metastasis of breast cancer cells \[[@R23], [@R34]\]. ITGB5 also promotes intracellular signaling by recruiting and activating integrin-associated kinases, including FAK, which contributes to chemoresistance in malignant disease. FAK, interacting with Src at Tyr861, plays a vital role in ITGB5-mediated signaling in response to vascular endothelial growth factor (VEGF) and Ras transformation in fibroblasts \[[@R31]\]. These features suggest that ITGB5 may participate in tumor cell adhesion, migration, inhibits metastasis, and angiogenesis, all of which may influence tumor prognosis. Our current study demonstrated that ITGB5 expression was related to HBV-related HCC prognosis, and the features of ITGB5 may play a role in HBV-related HCC prognosis, but this hypothesis still need further functional experiment investigation. ITGA2B, also known as platelet glycoprotein IIb of the IIb/IIIa complex, is the most abundant receptor on the platelet surface \[[@R35]\]. By binding platelets together, it has a significant role in hemostasis. Recent studies have suggested that platelets may contribute to the spread of cancer, and cancer patients may have both an elevated number of, and activated, platelets \[[@R36]\]. One study also reported that the platelet glycoprotein IIb/IIIa (GP IIb/IIIa) is crucial for the hematogenous metastasis of human breast carcinoma cells \[[@R37]\]. Based on previous research, these functions may play a role in the prognostic of ITGA2B expression in HBV-related HCC.

In previous reports, focus has been placed on investigating the biological behavior and prognostic roles of integrin family members in various cancers. Our results were consistent with a previous study, which found that the expression of *ITGA5* was associated with the prognosis of HBV-related HCC patients \[[@R34]\]. Furthermore, we found that the *ITGB5* expression level was higher in HCC tissues, while *ITGA2B* was higher in adjacent normal tissues. Furthermore, both of these genes were associated with the prognosis of HBV-related HCC patients. In addition, this is the first study to detect the prognostic predictive value of combining the expression of *ITGA5* with *ITGB5*. Finally, we found that the AG/GG genotypes at rs988574 (*ITGA1*) are significantly associated with better OS compared with carriers of the AA genotype in HBV-related HCC patients. The biggest challenge in this study was how to detect gene expression homogeneously since the data was influenced by various conditions, such as bias from the specific cell populations in the tumor tissues, the sampling sites and sample degradation, problems that have also occurred in other studies.

In summary, our study demonstrated that the expression of *ITGA5*, *ITGB5* and *ITGA2B*, as well as the genotype at rs988574 (*ITGA1*), may be potential independent prognostic bio-markers and therapeutic targets for HBV-related HCC patients and may be useful in the diagnosis of HBV-related HCC patients. Further studies focused on integrin family members and their downstream signaling pathways, as well as the effective blockage of integrins and their ECM interactions, will provide additional information about their use in cancer therapies.

METERIALS AND METHODS {#s4}
=====================

Ethical approval {#s4_1}
----------------

This study was performed in support of the Ethical Review Committee of the First Affiliated Hospital of Guangxi Medical University (Guangxi, China), and informed consent was obtained from all patients.

Study population {#s4_2}
----------------

A total of 485 newly diagnosed pathologically confirmed HBV-related HCC patients that had undergone surgical resection were recruited at the First Affiliated Hospital of Guangxi Medical University (Guangxi, China) from January 2005 to September 2014. All the patients were diagnosed by histopathological examination which followed the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for oncology. The patients were followed up via telephone or hospital visit until death or final follow-up in September 2014, for a median follow-up time of 47 months. None of the patients had a previous cancer diagnosis of any kind at the initial screening examination. The clinicopathological characteristics of patients including age, gender, smoking status, drinking status, pathological grade, biobehavior of their cancer, serum AFP level, hepatic cirrhosis, radical resection and use of transcatheter hepatic arterial chemoembolization (TACE) were obtained from medical records and pathological reports. Tumor status was classified according to the BCLC staging system. Child-Pugh class was defined as previously published. Portal vein tumor thrombus (PVTT) was determined to be absent or present. The endpoint was overall survival (OS), which was calculated from the date of pathological diagnosis/recruitment to death or the end of follow-up.

SNP selection, DNA extraction and genotyping {#s4_3}
--------------------------------------------

SNP selection tools (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>) were used to select candidate SNPs in integrin genes according a previous publication. The inclusion criteria were as follows: (i) SNPs in splice sites and CDS regions resulting in amino acid changes; SNPs in transcription factor binding sites of the 5' flanking region; and SNPs in miRNA binding sites of 3' UTR; and (ii) SNPs with minor allele frequency (MAF) ≥ 10% in the Han Chinese population (CHB) from the 1000 Genomes Project (March 2012, build GRCh37/hg19) \[[@R38]\]. These criteria resulted in18 SNPs being identified for assessment in this study (Table [8](#T8){ref-type="table"}).

###### Primers for SNPs of integrin genes

  SNPs             Primers          Sequences (5′-3′)                                       Annealing temperature (°C)   Amp Length (bp)
  ---------------- ---------------- ------------------------------------------------------- ---------------------------- -----------------
  **rs1531545**    ForwardReverse   ACAAGCTCTACCAGGTATCTGTATTCTTTCAAGCTATGAACTGCACGTTG      60                           274
  **rs4145748**    ForwardReverse   AGAGCATATTAAAAGCTTCCACCAACACCCATCCAACATGAAGACAAAG       62                           509
  **rs2279587**    ForwardReverse   GAAATGGAGTCCTGAGCGCTGTGGAGTGTTGAGGGCACTGCAT             62                           533
  **rs12520591**   ForwardReverse   CGTTTCAAGGTAAATGAATTCCCCTATGAGGCTTAGATCTCTAAACTGATGTG   61                           510
  **rs988574**     ForwardReverse   GAGGGAGGACAAGTGCACGGGCAATACCAGTCACTGCTTAAGGGA           62                           376
  **rs2230392**    ForwardReverse   CCCTCACCCAGAATAGGAGGAGGCCTCCATTTCTGCCTGCTTTACA          63                           580
  **rs1143674**    ForwardReverse   ATAGTGTTTGGCCCTTTTCAGGAATCTTCACTGGCAAGGCATTAAAA         61                           508
  **rs1143676**    ForwardReverse   TTGGCTGGGTTTTTGTGTTTCTGGACCCTGGGTCTATCTCAACTT           62                           494
  **rs7562325**    ForwardReverse   AAACCTCTAGCTAGAAGGTAAAGATCCGCCCATTTTCTTGCTGGTTCTAATA    62                           515
  **rs11895564**   ForwardReverse   GGAGTCCTGCTGTACTATGGTTCTCAGCAGCGCTATTATTTAAACAATCA      61                           501
  **rs1800974**    ForwardReverse   GTCCTCTTCCACCTTCTGCCTTTCAGTGTGGCCCAGCTCTTGAC            61                           493
  **rs2298033**    ForwardReverse   AATGGTTGGAATTTGGATATGAAGGAGATCTGATAGAGCACTGTGTTCACTG    60                           272
  **rs2507941**    ForwardReverse   GCACTCGTGGGAAGTGGCTGGGGCACAACCTGACTGAATGTC              60                           501
  **rs267561**     ForwardReverse   ATCCTGTTGGTCTAGTTCTTGTTTGTGGTCCAATGAGGCTTCAGTCTAG       62                           512
  **rs2274616**    ForwardReverse   GGGAAGCAAACACTGGGCTTGCTCCTTACCAGCACATGGAAGT             62                           492
  **rs2230433**    ForwardReverse   ATTTATTTCTTTCTGGCCCACCATAAACCTGGTACCTCGGATCATACA        60                           410
  **rs871443**     ForwardReverse   TAGGCACCTGTCCTTTCCTTCACCGAGTCGGGAGGACGCCTAGTG           62                           497
  **rs2291089**    ForwardReverse   AGCCGCACGTGCAGTTGTAGGGCTGGGAAGAGGATAGGACAGAA            62                           494

SNPs, single nucleotide polymorphisms.

HCC tissues collected after surgical resection from HBV-related HCC patients were immediately stored at −80°C until DNA extraction using the TIANamp Genomic DNA Kit (Tiangen Biotech, Beijing, China), and genotyping was performed using Sanger DNA sequencingby Shanghai Sangon Biological Engineering Technology & Services (Shanghai, China). All primers are shown in Table [8](#T8){ref-type="table"}.

Integrin gene mRNA expression analyses in HBV-related HCC tissues {#s4_4}
-----------------------------------------------------------------

In the present study, we focus on the Chinese HBV-related HCC. The Gene Expression Omnibus (GEO) data selection criteria were set as follows: (i) expression profiling chip; (ii) Chinese HBV-related HCC; (iii) corresponding survival profiles available; (iv) patients undergoing hepatectomy. By searching the GEO database, we found that only the data of GSE14520 met the above criteria. Data were analyzed with Expression Console software (<http://www.affymetrix.com/estore/index.jsp>). Probe signal values were converted to log2 values, and annotated genes were analyzed using the corresponding Affymetrix HT Human Genome U133A and Human Genome U133A_2 array annotation files. A multi-array average algorithm was used for normalization of the GSE14520 mRNA expression data. We analyzed the association between the mRNA expression of integrin genes and prognosis in 221 HBV-related HCC patients using data from the GSE14520. The 75th percentile was used to define higher versus lower expression.

Statistical analysis {#s4_5}
--------------------

The pearson correlation coefficient was used to assess the co-expression correlation of integrin genes in tumor mRNA. OS was defined as the time from surgery to death due to HCC and relapse-free survival (RFS) was defined as the time from surgery to disease recurrence. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by the Cox proportional hazards model after adjusting for factors such as age, gender, AFP level, tumor differentiation and treatment after surgery. GraphPad Prism 6 was used to plot Kaplan--Meier survival curves, scatter diagrams and histograms. Differences in the mRNA expression of integrin genes between HCC tissues and non-HCC tissues were evaluated using Student\'s t-test. Statistical significance was set at a level of *P* = 0.05, and all analyses were done using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA).

SUPPLEMENTARY MATERIALS FIGURE {#s5}
==============================
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